DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

Information source: Windy Hill Medical, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ductal Carcinoma In Situ

Intervention: Carboplatin i.d. Days 1 & 15 (Drug); Carboplatin i.d. Day 1; Normal Saline i.d. Day 15 (Drug); Normal Saline (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Windy Hill Medical, Inc.

Official(s) and/or principal investigator(s):
Jane Doerr, RN, MSN, Study Director, Affiliation: Windy Hill Medical, Inc.

Overall contact:
Jane Doerr, RN, MSN, Phone: 949-636-4737, Email: jdoerr@whmed.com

Summary

The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.

Clinical Details

Official title: A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion

Secondary outcome:

characterize i.d. carboplatin pharmacokinetics

characterize clinical extent of disease on MRI and/or mammogram

characterize the histopathological assessment of DCIS

Biomarker measurement of Ki-67, TUNEL and G-actin

Detailed description: This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i. e., 15 patients per arm) will receive two intraductal infusions of either 100 mg of carboplatin or NS on Days 1 and 15. Fifteen (15) patients will receive an intraductal infusion of 100 mg carboplatin on Day 1 and an intraductal infusion of NS on Day 15. Patients will undergo surgical resection 2 to 4 weeks following the Day 15 intraductal infusion (i. e. 4 to 6 weeks from diagnosis). The effect of carboplatin on DCIS in the pre-treatment core biopsy specimen and the resection specimen will be assessed. Venous blood samples will be collected for carboplatin PK analysis pre-dose and at 30 minutes, 1, 2, 4, and 8 hours following intraductal infusions on Days 1 and 15.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Female

- 18 years of age or older

- Scheduled to undergo surgical resection in 2 weeks or longer

- Pathological diagnosis of DCIS requiring surgical resection

- DCIS diagnosed with core biopsy

- Mammogram within 6 weeks of diagnosis

- Adequate organ function as defined by the following criteria:

Absolute neutrophil count (ANC) ≥ 1500/μl, Platelets ≥ 140,000/μl,Hemoglobin ≥ 12. 0 g/dl, Creatinine < 2. 0 mg/dl

- Able to sign informed consent

Exclusion Criteria:

- Current diagnosis of invasive or inflammatory breast carcinoma

- DCIS with microinvasion on histology on core needle biopsy

- Palpable mass

- Mass on mammography

- Concurrent anti-cancer therapy

- Prior exposure to carboplatin (related to current or past diagnosis)

- Prior radiation to the breast or chest wall

- Prior areolar or breast surgery which interrupts communication of the ductal systems

with the nipple

- Presence of breast implants

- Presence of ulcerating or fungal skin lesions or infection of the breasts

- Pregnant or lactating

- Impaired cardiac function or history of cardiac problems

- Poor nutritional state (as determined by clinician)

- Presence of serious infection

- Scheduled for intraoperative radiation of breast or chest wall

- Allergies to lidocaine or marcaine

- Allergies to imaging dyes

Locations and Contacts

Jane Doerr, RN, MSN, Phone: 949-636-4737, Email: jdoerr@whmed.com

OU Medical Center Laboratory, Oklahoma City, Oklahoma 73104, United States; Recruiting
William C Dooley, M.D., F.A.C.S., Phone: 405-206-5670, Email: William-Dooley@ouhsc.edu
Linda White, R.N., Phone: (949) 300-9576, Email: lwhite@whmed.com

MD Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
Henry Kuerer, M.D., Phone: 713-745-5043, Email: lboehnke@mdanderson.org
Linda White, R.N., Phone: 949 300-9576, Email: lwhite@whmed.com

Additional Information

Related publications:

Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer. 2004 Nov 1;101(9):1947-57.

Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11.

Khan SA, Wiley EL, Rodriguez N, Baird C, Ramakrishnan R, Nayar R, Bryk M, Bethke KB, Staradub VL, Wolfman J, Rademaker A, Ljung BM, Morrow M. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst. 2004 Oct 20;96(20):1510-7.

Starting date: May 2008
Last updated: October 1, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017